Clinical Case Of Severe Toxicoderma To Clofazimine In A Patient With Drug-Resistant Tuberculosis

This article presents a clinical case of a patient with drug-resistant pulmonary tuberculosis who developed a severe form of toxic-allergic dermatitis to the antitubercular drug clofazimine during complex chemotherapy. As a result of the comprehensive treatment, the patient showed positive clinical and radiological dynamics of the specific process, and the adverse reactions to clofazimine were corrected and, in some cases, resolved. Powerful detoxification and desensitization therapy, including medication and plasma exchange sessions, effectively addressed the adverse reactions. Clofazimine was removed from the chemotherapy regimen. The patient completed the full course of specific tuberculosis treatment on an outpatient basis with the outcome "Treatment completed."

1. Vol'f, S. B. (2016). Nezhelatel'nye pobochnye reakcii pri himioterapii tuberkuleza. Journal of the Grodno State Medical University, 3, 141-145. (In Russian).

2. Kukesa, V. G. and Starodubceva, A. K. (2012). Klinicheskaja farmakologija i farmakoterapija: uchebnik, Moscow, 840 p. (In Russian).

3. Mishin, V. Ju., Chukanov, V. I. and Grigor'ev, Ju. G. (2004). Pobochnoe dejstvie protivotuberkuleznyh preparatov pri standartnyh i individualizirovannyh rezhimah himioterapii. Moscow, 208 p. (In Russian).

4. Mozhokina, G. N. and Samojlova, A. G. (2021). Klofazimin: istorija i perspektivy. Tuberculosis and Lung Diseases, 99(5), 64-70. (In Russian).

5. Stepanova, N. A., Strel'cova, E. N., Galimzjanov, H. M. and Kantemirova, B. I. (2016). Nezhelatel'nye pobochnye reakcii na protivotuberkuleznye preparaty osnovnogo rjada. Tuberculosis and Lung Diseases, 5, 42-45. (In Russian).

6. Krylatova, Ju. F. and Babyreva, V. M. (1999). Farmakologija. GEOTAR – Media, Moscow, 350 p. (In Russian).

7. Mishin, V. Ju., Zavrazhnov, S. P., Mitronin, A. V. and Grigor'ev, Ju. G. (2016). Ftiziatrija: Uchebnik. GEOTAR – Media, Moscow, 520 p. (In Russian).

8. Homenko, A. G. (1996). Tuberkulez. Rukovodstvo dlja vrachej. Medicine, Moscow, 496 p. (In Russian).

9. Barry, V. C., Belton, J. G., Conalty, M. L., Denneny, J. M., Edward, D. W., O’Sullivan, J. F., Twomey, D. and Winder, F. (1957). A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature, 179, 1013-1015.

10. Cholo, M. C., Steel, H. C., Fourie, P. B., Germishuizen, W. A. and Anderson, R. (2012). Clofazimine: current status and future prospects. Journal of Antimicrobial Chemotherapy, 67, 290-298.

11. Irwin, S. M., Gruppo, V., Brooks, E., Gilliland, J., Scherman, M., Reichlen, M. J. et al. (2014). Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrobial Agents and Chemotherapy, 58(7), 4026-4034.

12. Jagannath, C., Reddy, M. V., Kailasam, S., O’Sullivan, J. F. and Gangadharam, P. R. (1995). Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. American Journal of Respiratory and Critical Care Medicine, 151, 1083-1086.

13. Van, Deun, Maug, A. K., Salim, M. A., Das, P. K., Sarker, M. R., Daru, P. and Rieder, H. L. (2010). Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine, 182, 684-692.

14. Global Tuberculosis report (2012). World Health Organization [Website]. Retrieved October 14, 2023, from https://www.who.int/publications/i/item/9789241564502.

15. WHO consolidated guidelines on drug-resistant tuberculosis treatment (2019). World Health Organization [Website]. Retrieved October 25, 2023, from https://www.who.int/publications/i/item/9789241550529.